Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Industry
Services-Medical Laboratories
Location
221 Crescent Street, Suite 103 A, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
MIRAGEN THERAPEUTICS, INC. (to 1/15/2021), SIGNAL GENETICS, INC. (to 2/10/2017), SIGNAL GENETICS LLC (to 7/9/2014)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.79K % +30.9%
Debt-to-equity 10.8 % +10.5%
Return On Equity -49.7 % +7.78%
Return On Assets -44.8 % +8.62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.9M shares +46.3%
Common Stock, Shares, Outstanding 63.9M shares +46.6%
Common Stock, Value, Issued 639K USD +46.6%
Weighted Average Number of Shares Outstanding, Basic 63.9M shares +47.6%
Weighted Average Number of Shares Outstanding, Diluted 63.9M shares +47.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 85M USD +42.1%
Operating Income (Loss) -251M USD -19.1%
Nonoperating Income (Expense) 22.7M USD +79.1%
Net Income (Loss) Attributable to Parent -228M USD -15.2%
Earnings Per Share, Basic -4.24 USD/shares +13.3%
Earnings Per Share, Diluted -4.24 USD/shares +13.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 571M USD +70.9%
Assets, Current 582M USD +68%
Property, Plant and Equipment, Net 1.51M USD -19.6%
Operating Lease, Right-of-Use Asset 1.83M USD -11.8%
Other Assets, Noncurrent 659K USD -44.3%
Assets 586M USD +66.6%
Accounts Payable, Current 3.14M USD -24%
Employee-related Liabilities, Current 9.04M USD +59.3%
Accrued Liabilities, Current 30.4M USD +25.3%
Contract with Customer, Liability, Current 288K USD 0%
Liabilities, Current 36.8M USD +28.3%
Contract with Customer, Liability, Noncurrent 428K USD -40.3%
Operating Lease, Liability, Noncurrent 1.6M USD +14.3%
Other Liabilities, Noncurrent 1.65M USD +7.92%
Liabilities 56.3M USD +58.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -543K USD -214%
Retained Earnings (Accumulated Deficit) -839M USD -37.3%
Stockholders' Equity Attributable to Parent 529M USD +67.6%
Liabilities and Equity 586M USD +66.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.2M USD +27%
Net Cash Provided by (Used in) Financing Activities 177M USD +2058%
Net Cash Provided by (Used in) Investing Activities -143M USD -976%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 63.9M shares +46.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD +83.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD +23.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 452K USD +304%
Deferred Tax Assets, Valuation Allowance 156M USD +79.8%
Deferred Tax Assets, Gross 156M USD +79.7%
Operating Lease, Liability 2.15M USD -3.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -228M USD -16%
Lessee, Operating Lease, Liability, to be Paid 2.65M USD +4.74%
Property, Plant and Equipment, Gross 2.72M USD -18.3%
Operating Lease, Liability, Current 507K USD -36.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 474K USD +1.72%
Lessee, Operating Lease, Liability, to be Paid, Year One 463K USD -52%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 498K USD +61.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 484K USD +2.11%
Deferred Tax Assets, Operating Loss Carryforwards 67.8M USD +47.3%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 494K USD +211%
Additional Paid in Capital 1.17B USD +47.6%
Depreciation, Depletion and Amortization 145K USD +38.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 64.1M USD +69.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%